Name | Gemcitabine |
Synonyms | NSC 613327 Gemcitabine gemicitabine gencitabine base Gemcitabine Base GEMCITABINE HCL USP 2',2'-Difluorodeoxycytidine 2'-deoxy-2',2'-difluorocytidine 2'-Deoxy-2',2'-difluoro-D-cytidine Cytidine, 2'-deoxy-2',2'-difluoro- 2'-Deoxy-2',2'-difluro cytidine Hydrochloride 2''-DEOXY-2'',2''-DIFLUOROCYTIDINE(GEMCITABINE) 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one |
CAS | 95058-81-4 |
EINECS | 619-100-6 |
InChI | InChI=1/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7?/m1/s1 |
Molecular Formula | C9H11F2N3O4 |
Molar Mass | 263.2 |
Density | 1.84±0.1 g/cm3(Predicted) |
Melting Point | 168,64 C |
Boling Point | 482.7±55.0 °C(Predicted) |
Specific Rotation(α) | 365 +425.36°; D +71.51° |
Flash Point | 245.724°C |
Solubility | DMSO 15 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Vapor Presure | 0mmHg at 25°C |
Appearance | Powder |
Color | White to Off-White |
pKa | 11.65±0.70(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
Refractive Index | 1.652 |
MDL | MFCD00869720 |
Physical and Chemical Properties | For advanced and metastatic pancreatic cancer. |
Use | Usage: suitable for the treatment of advanced non-small cell lung cancer |
Risk Codes | R21 - Harmful in contact with skin R36/38 - Irritating to eyes and skin. R46 - May cause heritable genetic damage R62 - Possible risk of impaired fertility R63 - Possible risk of harm to the unborn child |
Safety Description | S25 - Avoid contact with eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use. |
HS Code | 29349990 |
Toxicity | LD10 i.v. in rats: 200 mg/m2 (Abbruzzese) |
Reference Show more | 1. [IF=6.304] Xiong Qiao et al."Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer."Cell Death Dis. 2020 May;11(5):1-13 2. [IF=2.311] Shanshan Jiang et al."Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process."Oncol Lett. 2020 Jul;20(1):346-356 |